Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis

Paolo MilaniAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Stefan SchönlandAmyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

Giovanni PalladiniAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and Correspondence[email protected]

Christoph KimmichAmyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

Marco BassetAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Francesca RussoAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Andrea FoliAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Stefano PerliniAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Tilmann BochtlerAmyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

Anthony D. HoAmyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

Giampaolo MerliniAmyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy, ;Department of Molecular Medicine, University of Pavia, Pavia, Italy, and

Ute HegenbartAmyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

show all

References

Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016;128:159–68.
PubMed Web of Science ®Google Scholar
Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–501.
PubMed Web of Science ®Google Scholar
Fernandez de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015;125:2239–44.
PubMed Web of Science ®Google Scholar
Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012;119:488–93.
PubMed Web of Science ®Google Scholar
Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844–7.
PubMed Web of Science ®Google Scholar
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9.
PubMed Web of Science ®Google Scholar
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325–32.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date